Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Homeostasis of intracranial pressure (ICP) refers to the dynamic regulation of pressure inside the skull, maintained by compensatory changes in the volumes of three main intracranial components: brain tissue, cerebrospinal fluid (CSF), and blood[5][4][6]. Changes in any of these compartments are balanced according to the Monro-Kellie doctrine, which dictates that the sum volume within the cranium is fixed and that shifts in one must be offset by others[5][3][4]. ICP regulation is critically important for adequate cerebral perfusion; dysfunction leads to neurological injury, such as cerebral ischemia or herniation[4][6]. Although drugs and interventions can target the consequences or components affecting ICP, there is no single molecule or receptor representing "intracranial pressure homeostasis"[5][6][7].
Osmotic diuretics reduce cerebral edema by drawing fluid out of brain tissue Hypertonic solutions reduce ICP by increasing plasma osmolarity Acetazolamide reduces CSF production Barbiturates lower cerebral metabolism and blood flow
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intracranial pressure homeostasis.